Evidence map›Paper›PMID 41326575›Full record

ArticleScientific reports2025

Automated classification of lung cancer subtypes cells using microscopic images and ensembled deep learning architectures.

Maheswari Vutukuri, Parveen Sultana Habibullah

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Maheswari VutukuriSchool of Computer Science and Engineering, Vellore Institute of Technology, Vellore, India.
Parveen Sultana HabibullahSchool of Computer Science and Engineering, Vellore Institute of Technology, Vellore, India. hparveensultana@vit.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the intricate domain of lung cancer diagnostics, this research presents a groundbreaking for the early detection of lung cancer at the cellular level which remains a critical challenge due to the subtle morphological differences among its subtypes. This study introduces a hybridized deep-learning framework that combines the global feature expertise of ResNet-50 with the spatial-attention capabilities of Attention U-Net to analyse microscopic images of individual lung cells. A comprehensive image-processing pipeline featuring Contrast Limited Adaptive Histogram Equalization (CLAHE), median-filter for denoising, Otsu's adaptive thresholding for feature extraction and targeted grey- midtone lightening to amplify diagnostically irrelevant textures and suppresses artifacts, which boosts the signal-to-noise ratio by 23%. Using a balanced dataset of 4,650 grayscale images (1,500 per subtype) and enriched extensive image augmentations the model learned robust representations across adenocarcinoma, neuroendocrine carcinoma, and squamous cell carcinoma. On a 25% hold-out test set, it achieved 99.85% overall accuracy, with precision, recall, and F1-scores all exceeding 0.99 (for neuroendocrine carcinoma). Five-fold stratified cross-validation confirmed this performance (mean accuracy 99.69% ± 0.16%), demonstrating exceptional consistency and minimal variance. By detecting cancer at its very inception in single-cell images, this approach paves the way for ultra early diagnostics and personalized treatment planning in clinical practice at the very initially cellular level.

Indexed as

Deep LearningImage Processing, Computer-AssistedLung NeoplasmsMicroscopyHumansAdaptive thresholdingAttention U-NetCross validationDeep learningLung cancer diagnosticsResNet-50Suppresses artifacts

Identifiers

PMID41326575
PMCPMC12770512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.